The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Impact of Androgen-Deprivation Therapy on Physical Function and Quality of Life in Men With Nonmetastatic Prostate Cancer
Abstract
Purpose: This prospective longitudinal study evaluated the effect of androgen deprivation therapy (ADT) on objective and self-reported physical function. Patients and Methods: Men with nonmetastatic prostate cancer (PC) starting continuous ADT were enrolled in this matched cohort study. Physical function was assessed with the 6-minute walk test (6MWT), grip strength, and the timed-up-and-go (TUG) test, representing endurance and upper and lower extremity strength, respectively. Quality of life (QOL) was measured with the Medical Outcomes Study Short-Form 36 (SF-36) questionnaire. Subjects were assessed at baseline, 3, 6, and 12 months. Two control groups (PC without ADT; no PC), matched on age, education, and baseline function were enrolled. Mixed effects regression models were fitted, adjusting for baseline covariates. Results: We enrolled 87 patients on ADT, 86 PC controls, and 86 healthy controls; groups were similar in age (mean, 69.1 years; range, 50 to 87) and physical function. The 6MWT distance remained stable in the ADT group (P = .96) but improved in both control groups (P < .05). Grip strength declined in the ADT group (P = .04), remained stable in PC controls (P = .31), and improved in healthy controls (P = .008). TUG scores remained stable over time and across groups (P > .10). The SF-36 physical function summary score declined in the ADT group (P < .001), but increased in both control groups (P < .001). Negative effects on outcomes were observed within 3 months of starting ADT and were generally independent of age. Conclusion: Endurance, upper extremity strength, and physical components of QOL are affected within 3 months of starting ADT. Up-front exercise interventions to counteract these losses are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living
Lawton, M. P., & Brody, E. M. (1969) · The Gerontologist · doi:10.1093/geront/9.3_part_1.179 · Cited by 18,540
The Timed “Up & Go”: A Test of Basic Functional Mobility for Frail Elderly Persons
Podsiadlo, D., & Richardson, S. (1991) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1991.tb01616.x · Cited by 14,418
ATS Statement: Guidelines for the Six-Minute Walk Test
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.166.1.at1102 · Cited by 11,195
No adjustments are needed for multiple comparisons.
Rothman, K. J. (1990) · Epidemiology · doi:10.1097/00001648-199001000-00010 · Cited by 5,965
Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09408-4 · Cited by 1,686 · cited 1×
“Approximately 50% of men with prostate cancer (PC) will receive androgen deprivation therapy (ADT) at some time after diagnosis,(1) and most will take it for at least 2 to 3 years.(2,3) ADT is associated with numerous adverse effects, including poorer quality of life (QOL), sexual dysfunction, fatigue, anemia, loss of…”
BackgroundSelf-citationTwo-, six-, and 12-minute walking tests in respiratory disease.
Butland, R. J., Pang, J., Gross, E. R., Woodcock, A. A., & Geddes, D. M. (1982) · BMJ · doi:10.1136/bmj.284.6329.1607 · Cited by 1,668
Redelmeier, D. A., Bayoumi, A. M., Goldstein, R. S., & Guyatt, G. H. (1997) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.155.4.9105067 · Cited by 1,029 · cited 2×
“For the 6MWT, simulation-based modeling with 1,000 data sets was performed to estimate power against a MCID of 54 meters.(46) At each time point, we used a between-subject standard deviation of 93 meters.”
MethodResultNewman, A. B., Simonsick, E. M., Naydeck, B. L., Boudreau, R. M., Kritchevsky, S. B., Nevitt, M. C., Pahor, M., Satterfield, S., Brach, J. S., Studenski, S. A., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2018 · Cited by 934
Segal, R. J., Reid, R. D., Courneya, K. S., Sigal, R. J., Kenny, G. P., Prud'Homme, D. G., Malone, S. C., Wells, G. A., Scott, C. G., & Slovinec D'Angelo, M. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4963 · Cited by 554
Onder, G., Penninx, B. W. J. H., Ferrucci, L., Fried, L. P., Guralnik, J. M., & Pahor, M. (2005) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/60.1.74 · Cited by 347
Aging successfully until death in old age: opportunities for increasing active life expectancy
Leveille, S. G., Guralnik, J. M., Ferrucci, L., & Langlois, J. A. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009866 · Cited by 301
HERR, H. W., & O’SULLIVAN, M. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67533-7 · Cited by 250
Alibhai, S. M. H., Gogov, S., & Allibhai, Z. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.06.006 · Cited by 173
Self-citation
Cited by
Cormie, P., Galvão, D. A., Spry, N., Joseph, D., Chee, R., Taaffe, D. R., Chambers, S. K., & Newton, R. U. (2015) · BJU International · doi:10.1111/bju.12646 · Cited by 277
Storer, T. W., Miciek, R., & Travison, T. G. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2011.104 · Cited by 70
Karnes, R. J., Sharma, V., Choeurng, V., Ashab, H. A.-D., Erho, N., Alshalalfa, M., Trock, B., Ross, A., Yousefi, K., Tsai, H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2745 · Cited by 30
“Nevertheless, despite its potential benefits, ADT has been associated with cardiovascular, thrombotic, and cognitive sideeffects in addition to its detrimental impact on quality of life (11).”
Background
Metadata
- Authors
- Alibhai, S. M. H., Breunis, H., Timilshina, N., Johnston, C., Tomlinson, G., Tannock, I., Krahn, M., Fleshner, N. E., Warde, P., Canning, S. D., Klotz, L., & Naglie, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-12-01
- Volume
- 28
- Issue
- 34
- Pages
- 5038-5045
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2102818606
- Cited by
- 183
- References
- 13
- FWCI
- 11.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.